Ferring
PharmaSaint-Prex, Switzerland · Est. 1950
Ferring is a privately-held Swiss pharmaceutical company focused on specialty pharmaceuticals in reproductive health, gastroenterology, and endocrinology.
3
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
10
Indications↗
Distinct diseases across all programs
210
Clinical Trials↗
All sponsored trials (all statuses)
21
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
3 drugs in development
Approved1
Phase 32
Phase 21
Phase 11
Preclinical1
By Therapeutic Area
top 5
Oncology
225%
Metabolic & Endocrine
113%
Infectious Disease
113%
Cardiovascular
113%
Gastroenterology
113%
R&D Momentum
32/100
Pipeline Velocity
6/100
Trial Completion Rate
84/100
Pipeline Concentration
19/100
Pipeline Freshness
76/100
Strategic Signals
- ↗Active in Oncology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Recruiting
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Jul 9, 2026
Recruiting
A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Earlier
Feb 25, 2026FDADDAVP — DESMODA
Sep 12, 2025TrialA Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump
Jun 12, 2025TrialLow-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Aug 27, 2024TrialProspective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings
Jul 15, 2024TrialAn Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.
Jul 1, 2024TrialInvestigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons
4 more events
Jun 17, 2024TrialA Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
Jun 14, 2024TrialAn Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation
Mar 29, 2024TrialA Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China
Mar 12, 2024TrialA Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
Reproductive healthGastroenterologyEndocrinology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Gastroenterology
Infectious Disease
Metabolic & Endocrine
Oncology
Cardiovascular
Portal Hypertension
FE 999301Phase 1
Gastroenterology
Constipation
MiralaxPreclinical
Infectious Disease
Septic Shock
FE 999301Phase 2
Metabolic & Endocrine
Oncology
Unknown / Other
Regulatory
Regulatory Timeline
19824 events
FDASep 30
Factrel — FACTREL
Application NDA018123 (NDA)
FDAJan 1
DDAVP — DDAVP
Application NDA017922 (NDA)
FDAJan 1
Prometrium — PROGESTASERT
Application NDA017553 (NDA)
FDAJan 1
Prometrium — PROGESTERONE
Application NDA009238 (NDA)
19841 event
FDAMar 30
DDAVP — DDAVP
Application NDA018938 (NDA)
19891 event
FDAOct 10
Factrel — LUTREPULSE KIT
Application NDA019687 (NDA)
19901 event
FDADec 26
DDAVP — CONCENTRAID
Application NDA019776 (NDA)
19941 event
FDAMar 7
DDAVP — STIMATE
Application NDA020355 (NDA)
19951 event
FDASep 6
DDAVP — DDAVP
Application NDA019955 (NDA)
19971 event
FDAJul 31
Prometrium — CRINONE
Application NDA020701 (NDA)
19981 event
FDAMay 14
Prometrium — PROMETRIUM
Application NDA019781 (NDA)
20021 event
FDASep 16
DDAVP — MINIRIN
Application NDA021333 (NDA)
20041 event
FDAOct 29
MENOPUR — MENOPUR
Application BLA021663 (BLA)
20071 event
FDAJun 21
Prometrium — ENDOMETRIN
Application NDA022057 (NDA)
20082 events
FDADec 24
Firmagon — FIRMAGON
Application NDA022201 (NDA)
FDAMay 8
DDAVP — DESMOPRESSIN ACETATE
Application NDA021795 (NDA)
20171 event
FDAMar 3
DDAVP — NOCTIVA
Application NDA201656 (NDA)
20181 event
FDAJun 21
DDAVP — NOCDURNA
Application NDA022517 (NDA)
20201 event
FDAApr 29
Prometrium — MILPROSA
Application NDA201110 (NDA)
20261 event
FDAFeb 25
DDAVP — DESMODA
Application NDA219873 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)